Vectura Share Discussion Threads

[popper joe] 02/12/2016 17:18

Is anyone able to offer a clear explanation of what this issue with GSK is about? My reading of the situation is that the 2010 agreement between the two companies covered the licensed use by GSK of technologies that VEC had patents over. It would appear that those patents expired in 2016 and GSK are now refusing to pay a license fee for the continued use of now un-patented technology. Am I missing something, because from my naive VEC shareholder's point of view, I can't see that we have much of an argument.

[fhmktg] 02/12/2016 16:58

Not if they are suing in the US!

[carpadium] 02/12/2016 16:50

Four months and counting since litigation initiated. Maybe the Christmas spirit will prevail and relationship restored but wouldn't put money on that happening.

[dontay] 02/12/2016 16:32

Carpadium... thank you for that. I doubt in the general scheme of things... now that Novartis have been awarded the gold medal for the other products... that it will matter much. With so much money involved GSK are almost obligated to try it on to see what they can get away with and companies the size of VEC have to fight their corner. Its almost a game. Hopefully the patent issues will anyway be all be settled out of court and the only folk that end up being disappointed are the lawyers.

[dontay] 02/12/2016 13:19

Is this one of the drugs that is subject to litigation?GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today (2/12/16) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptoms with chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate 'FF', and the long-acting beta2 agonist (LABA), vilanterol 'VI'. The approved dose of FF/VI in chronic obstructive pulmonary disease (COPD) is 100/25 mcg administered once-daily using the Ellipta dry powder inhaler (DPI). Relvar Ellipta has been approved in Japan for the treatment of asthma since 2013 in two strengths - 100/25 mcg and 200/25 mcg.

[richtea1701] 02/12/2016 11:09

Low volume

[alexchry] 02/12/2016 10:22

It's hard to believe that this drop in share price doesn't indicate bad news to follow, I do hope it's just nervousness but I fear the worst. However, I've held SKP and now VEC for over 12 years so I'm not going to bail out just yet.

[a1ord53] 01/12/2016 17:13

Jdgen,vec share price was up to 200p and GBP was 1,50$
now 1£=1,26$ and share price 140p
15% currency tailwind for profit but looks like we have headwind for sp
its because brokers wrong with their 200p -250p targets and market is right

who produces Nucala ?

[carpadium] 01/12/2016 16:48

Nucala, £840 a dose!!

[carpadium] 01/12/2016 16:46

Yep, a pound santa rally won't help a VEC santa rally BUT decent news pre-Christmas from the land of gnomes would trump any such inconvenience.

[mundungus] 01/12/2016 16:43

Today's Telegraph: The National Institute for Health and Care Excellence (Nice) has said mepolizumab, sold under the brand name Nucala, should be available to patients through the NHS who suffer from a severe type of asthma.

Nucala is a new class of asthma drug called a biologic, which targets special white blood cells that cause inflammation and breathing difficulties in many people with asthma.

[jdgen] 01/12/2016 16:32

One of the reasons for today's decline is that pharma royalty income is in US dollars and pound has strengthened.Therefore less sterling income. But not an issue as 140 provides another buy opportunity. Keep the faith.

[a1ord53] 01/12/2016 16:25

upgrade by broker from 200 to 220p today and share price 140 from 150p
Vec is disaster for many of us
merger with Skp brought us misery and

[pooroldboy55] 01/12/2016 15:59

A bit later for the big sale off today but same old same old

[fhmktg] 30/11/2016 20:29

Swiss diplomacy!

[carpadium] 30/11/2016 17:24

Could well be fhmktg.

By the way, I sent an enquiring email to Novartis yesterday and received similar to yourself. Not very enlightening but I'll print it anyway!

Thank you for your mail!

What we have said on this is that we first need to analyze the results of two head-to-head studies comparing Utibron to Anoro. Once this has been done, we’ll announce our plans for Utibron.

In your own time Novartis.

[fhmktg] 30/11/2016 17:08

Isn't it the day traders balancing their books?

[carpadium] 30/11/2016 17:00

pob..every trading day, at 16.35, a volume quantity is recorded, denoted as neither a buy nor sell. Check back as far as you want, it means nothing in terms of a signal for future trading.

[pooroldboy55] 30/11/2016 16:42

Not looking good for tomorrow sell off 750000 below days low @ 143 perhaps news is out there somewhere,

[pooroldboy55] 30/11/2016 16:24

Yes this is not looking to good at the moment know one thing for sure don't buy in the morning, The only good thing is the directors buying a few weeks back let's hope they are in the know! !!!

[alexchry] 30/11/2016 16:04

pooroldboy55-the afternoon sell-off seems worse than usual, particularly as there was no morning rise. I hope that it's just nervousness ahead of the Novartis marketing decision rather than bad news seeping out ahead of a formal announcement but it won't be the first time weakness has preceded bad news.

[pooroldboy55] 30/11/2016 13:11

Usual afternoon sell off